Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 711 participants.

Also called NCT01968954

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 711 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01968954
  • EudraCT 2013-002642-37
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Czechia, Germany, Hong Kong SAR China, Italy, Poland, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01968954. Randomized; quadruple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2016-04 (actual). Results posted on 2017-05-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Acronym
SPIRE-HR
Condition
Hyperlipidemia
Intervention (Drug)
Bococizumab (PF-04950615;RN316)
Intervention (Other)
Placebo
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01968954
Content hash
6a38492cc181a977a73e93fe9203308ba554ed01c96c0b76ea41aba61e6ce85f